KB-1102

Teprotumumab

Background

Thyroid eye disease (TED) is a complex autoimmune condition that results in disfiguring orbital changes that may be associated with the development of diplopia and optic neuropathy. Strong evidence has implicated the insulin-like growth factor I receptor (IGF-IR) in the pathogenesis of this disease. Teprotumumab is a fully human monoclonal immunoglobulin G1 to IGF-1R that was recently approved for the treatment of TED in the USA. Binding of teprotumumab inhibits signaling through the IGF-R1/TSH-R complex and the downstream pathways.

Specifications

Catalog Number:
KB-1102
Cell Line Name:
Teprotumumab
Price:
0
Host Cell Line:
EXPI-CHO
Target:
IGF1R
Species Reactivity:
Human
Application:
FACS | Blocking assay
Purification Method:
Affinity purified
Concentration:
>2mg/mL
Purity:
>95% by SDS-PAGE and SEC-HPLC
Endotoxin Level:
<0.5 EU/mg as determined by the LAL method
Sterility:
0.2μm filtered
Formulation:
20mM sodium citrate,150mM NaCl, pH5.5
Storage:
Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.
Bio Safety Level:
1
Validation:
SDS-PAGE | SEC-HPLC | FACS | Blocking assay

References

1.Wang Y, Patel A, Douglas RS. Thyroid eye disease: how a novel therapy may change the treatment paradigm. Ther Clin Risk Manag. 2019;15:1305–18. 2.Smith TJ, Kahaly GJ, Ezra DG, Fleming JC, Dailey RA, Tang RA, et al. Teprotumumab for thyroid-associated ophthalmopathy. N Engl J Med. 2017;376:1748–61. 3.Douglas RS, Kahaly GJ, Patel A, Sile S, Thompson EHZ, Perdok R, et al. Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med. 2020;382:341–52.
Please enable JavaScript in your browser to complete this form.